Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1157)	6/1/2000 4:54:00 PM
From: nohalo	Read Replies (1) \| Respond to of 52153

I disagree, with respect. Double blind trials are designed in such a way that the investigator (doctor or nurse) has no knowledge of which of their patients are getting the active drug. Strict criteria are established for these double blind trials. Granted, some insider trading may occur, but in most cases, the field investigators are not involved. Also, most trials are multi-center trials, and doctors in the field will not know the overall outcome until the data is published. Leakage should never occur, but when it does, generally, the doctors and nurses are not the cause.